NASDAQ:AERI - Aerie Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$49.65 -0.30 (-0.60 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$49.65
Today's Range$48.90 - $50.20
52-Week Range$47.05 - $66.60
Volume219,413 shs
Average Volume327,968 shs
Market Capitalization$2.02 billion
P/E Ratio-14.73
Dividend YieldN/A
Beta0.96

About Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300

Debt

Debt-to-Equity Ratio0.52
Current Ratio13.57
Quick Ratio13.53

Price-To-Earnings

Trailing P/E Ratio-14.73
Forward P/E Ratio-13.24
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.98 per share
Price / Book8.30

Profitability

EPS (Most Recent Fiscal Year)($3.37)
Net Income$-145,100,000.00
Net MarginsN/A
Return on Equity-84.90%
Return on Assets-46.26%

Miscellaneous

Employees160
Outstanding Shares39,500,000

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals (NASDAQ:AERI) announced its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.04. View Aerie Pharmaceuticals' Earnings History.

What price target have analysts set for AERI?

11 brokers have issued twelve-month target prices for Aerie Pharmaceuticals' shares. Their forecasts range from $68.00 to $100.00. On average, they expect Aerie Pharmaceuticals' share price to reach $79.00 in the next twelve months. View Analyst Ratings for Aerie Pharmaceuticals.

What are Wall Street analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
  • 1. Canaccord Genuity analysts commented, "We continue to view Aerie positively, with catalysts for Roclatan, OUS geographies and additional clinical progression as potential inflection points that build on what will likely be solid acceptance of Rhopressa. We maintain our BUY rating and DCF-driven $86 PT on AERI shares." (5/15/2018)
  • 2. Mizuho analysts commented, "We remain confident in the management team as the Rhopressa launch progresses and reiterate our Buy rating on the stock." (5/9/2018)
  • 3. According to Zacks Investment Research, "Aerie received a significant boost with the recent approval of lead drug Rhopressa. The approval came ahead of the PDUFA date. Meanwhile, Aerie is also evaluating Roclatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Aerie’s shares have outperformed the industry in the last  twelve months. However, Rhopressa faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan, as well as other smaller biotechnology and pharmaceutical companies. Valeant Pharmaceutical’s Vyzulta is also approved for open-angle glaucoma or ocular hypertension. Rhopressa will face a tough time in gaining market share due to competition from these products. Any approval delays for Roclatan like Rhopressa will be detrimental to the company's growth prospects." (4/17/2018)

Who are some of Aerie Pharmaceuticals' key competitors?

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the folowing people:
  • Dr. Vincente J. Anido Jr., Ph.D., Chairman & CEO (Age 65)
  • Mr. Thomas A. Mitro, Pres & COO (Age 60)
  • Mr. Richard James Rubino CPA, CFO & Sec. (Age 60)
  • Dr. Casey C. Kopczynski Ph.D., Co-Founder & Chief Scientific Officer (Age 57)
  • Ms. Jessica Crespo CPA, Director of Accounting

Has Aerie Pharmaceuticals been receiving favorable news coverage?

Media stories about AERI stock have trended somewhat positive on Friday, Accern reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a media sentiment score of 0.21 on Accern's scale. They also assigned media headlines about the company an impact score of 46.65 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.95%), Columbus Circle Investors (1.60%), Summit Trail Advisors LLC (1.11%), Northern Trust Corp (1.10%), Millennium Management LLC (0.98%) and Neuberger Berman Group LLC (0.81%). Company insiders that own Aerie Pharmaceuticals stock include Foresite Capital Fund Ii, LP, Geoffrey M Duyk and Gerald D Cagle. View Institutional Ownership Trends for Aerie Pharmaceuticals.

Which institutional investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Barclays PLC, Russell Investments Group Ltd., Citigroup Inc., Suffolk Capital Management LLC, BlackRock Inc., Millennium Management LLC and Eversept Partners LLC. View Insider Buying and Selling for Aerie Pharmaceuticals.

Which institutional investors are buying Aerie Pharmaceuticals stock?

AERI stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Highland Capital Management LP, Handelsbanken Fonder AB, Handelsbanken Fonder AB, OppenheimerFunds Inc., Neuberger Berman Group LLC, PointState Capital LP and Columbus Circle Investors. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP and Gerald D Cagle. View Insider Buying and Selling for Aerie Pharmaceuticals.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $49.65.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $2.02 billion. The company earns $-145,100,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Aerie Pharmaceuticals employs 160 workers across the globe.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]


MarketBeat Community Rating for Aerie Pharmaceuticals (AERI)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  481 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  630
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aerie Pharmaceuticals (NASDAQ:AERI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Aerie Pharmaceuticals in the last 12 months. Their average twelve-month price target is $79.00, suggesting that the stock has a possible upside of 59.11%. The high price target for AERI is $100.00 and the low price target for AERI is $68.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.922.92
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $79.00$79.9091$74.8462$71.8462
Price Target Upside: 59.11% upside47.30% upside39.51% upside20.35% upside

Aerie Pharmaceuticals (NASDAQ:AERI) Consensus Price Target History

Price Target History for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ:AERI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018Canaccord GenuitySet Price TargetBuy$86.00LowView Rating Details
5/9/2018HC WainwrightSet Price TargetBuy$78.00LowView Rating Details
5/9/2018MizuhoReiterated RatingBuy$77.00LowView Rating Details
5/8/2018Cantor FitzgeraldSet Price TargetBuy$86.00LowView Rating Details
3/5/2018Seaport Global SecuritiesReiterated RatingBuyMediumView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$80.00N/AView Rating Details
10/16/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$65.00 ➝ $76.00N/AView Rating Details
10/11/2017JMP SecuritiesSet Price TargetBuy$68.00N/AView Rating Details
10/5/2017CowenReiterated RatingBuyN/AView Rating Details
7/28/2017Stifel NicolausReiterated RatingBuy$70.00MediumView Rating Details
5/25/2017AegisBoost Price TargetBuy$63.00 ➝ $70.00HighView Rating Details
3/9/2017Raymond JamesDowngradeStrong-Buy ➝ Market Perform$48.00LowView Rating Details
3/8/2017Royal Bank of CanadaBoost Price TargetOutperform$54.00 ➝ $55.00MediumView Rating Details
2/17/2017Roth CapitalInitiated CoverageBuy$69.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$48.00 ➝ $63.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Aerie Pharmaceuticals (NASDAQ:AERI) Earnings History and Estimates Chart

Earnings by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ:AERI) Earnings Estimates

2018 EPS Consensus Estimate: ($3.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.86)($0.86)($0.86)
Q2 20181($0.82)($0.82)($0.82)
Q3 20181($0.84)($0.84)($0.84)
Q4 20181($0.79)($0.79)($0.79)

Aerie Pharmaceuticals (NASDAQ AERI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1($0.87)($0.83)ViewListenView Earnings Details
2/28/2018Q4 2017($1.2110)($1.38)ViewListenView Earnings Details
11/8/2017Q3 2017($0.89)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.84)($0.82)ViewListenView Earnings Details
5/2/2017Q1 2017($0.74)($0.76)ViewListenView Earnings Details
3/7/2017Q4 2016($0.67)($0.87)ViewListenView Earnings Details
11/2/2016Q316($0.70)($0.67)ViewN/AView Earnings Details
8/3/2016Q216($0.74)($0.72)ViewN/AView Earnings Details
5/2/2016Q116($0.64)($0.72)ViewN/AView Earnings Details
3/1/2016Q415($0.72)($0.64)ViewN/AView Earnings Details
11/3/2015Q315($0.66)($0.69)ViewN/AView Earnings Details
8/5/2015Q215($0.70)($0.73)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.62)($0.70)ViewListenView Earnings Details
3/2/2015Q414($0.51)($0.69)ViewN/AView Earnings Details
11/11/2014Q3 2014($0.40)($0.54)ViewN/AView Earnings Details
8/6/2014Q2 2014($0.37)($0.49)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.35)($0.28)ViewN/AView Earnings Details
3/18/2014Q413($0.25)($0.62)ViewN/AView Earnings Details
12/4/2013Q313($0.25)($10.81)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aerie Pharmaceuticals (NASDAQ:AERI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aerie Pharmaceuticals (NASDAQ AERI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.53%
Insider Trading History for Aerie Pharmaceuticals (NASDAQ:AERI)
Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ AERI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/25/2018Gerald D CagleDirectorBuy1,000$49.45$49,450.0016,050View SEC Filing  
5/21/2018Gerald D CagleDirectorBuy1,000$50.25$50,250.0015,050View SEC Filing  
5/26/2017Foresite Capital Fund Ii, L.P.Major ShareholderSell20,000$55.95$1,119,000.00View SEC Filing  
4/19/2017Gerald D CagleDirectorBuy2,000$41.70$83,400.0010,900View SEC Filing  
2/15/2017Geoffrey M DuykDirectorSell41,591$46.63$1,939,388.3310,067View SEC Filing  
10/6/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell50,000$40.34$2,017,000.00View SEC Filing  
7/22/2016Foresite Capital Fund Ii, L.P.Major ShareholderBuy250,000$17.50$4,375,000.00View SEC Filing  
4/15/2015Anand MehraDirectorSell425,000$33.64$14,297,000.00View SEC Filing  
1/8/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell175,000$31.11$5,444,250.00View SEC Filing  
1/5/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell23,620$30.86$728,913.20View SEC Filing  
12/29/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell80,724$30.05$2,425,756.20View SEC Filing  
12/23/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,704$30.36$1,509,013.44View SEC Filing  
12/22/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,441$30.36$1,501,028.76View SEC Filing  
11/25/2014Anand MehraDirectorSell800,000$26.00$20,800,000.00View SEC Filing  
11/25/2014Group Holdings (Sbs) Advis TpgInsiderSell1,300,000$25.97$33,761,000.00View SEC Filing  
7/10/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,000,000$25.17$25,170,000.00View SEC Filing  
7/9/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell500,000$25.05$12,525,000.00View SEC Filing  
5/22/2014Anand MehraDirectorSell323,932$16.00$5,182,912.00View SEC Filing  
5/22/2014Iv L.P. AcpMajor ShareholderSell300,000$16.00$4,800,000.00View SEC Filing  
5/16/2014Gerald CagleDirectorBuy1,854$15.07$27,939.781,854View SEC Filing  
10/30/2013Brian LevyInsiderBuy6,000$10.00$60,000.00View SEC Filing  
10/30/2013Iv L.P. AcpMajor ShareholderBuy110,000$10.00$1,100,000.00View SEC Filing  
10/30/2013Richard J RubinoCFOBuy10,000$10.00$100,000.00View SEC Filing  
10/30/2013Thomas A MitroCOOBuy5,000$10.00$50,000.00View SEC Filing  
10/30/2013Vicente Anido JrCEOBuy28,000$10.00$280,000.00View SEC Filing  
10/25/2013Anand MehraDirectorBuy285,000$10.00$2,850,000.00View SEC Filing  
10/25/2013Lifesciences Ii L.P. ClarusMajor ShareholderBuy321,000$10.00$3,210,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aerie Pharmaceuticals (NASDAQ AERI) News Headlines

Source:
DateHeadline
Aerie Pharmaceuticals (AERI) Director Buys $49,450.00 in StockAerie Pharmaceuticals (AERI) Director Buys $49,450.00 in Stock
www.americanbankingnews.com - May 25 at 4:19 PM
Zacks: Brokerages Anticipate Aerie Pharmaceuticals (AERI) Will Post Quarterly Sales of $1.16 MillionZacks: Brokerages Anticipate Aerie Pharmaceuticals (AERI) Will Post Quarterly Sales of $1.16 Million
www.americanbankingnews.com - May 25 at 4:51 AM
Zacks: Brokerages Anticipate Aerie Pharmaceuticals (AERI) Will Post Earnings of -$0.96 Per ShareZacks: Brokerages Anticipate Aerie Pharmaceuticals (AERI) Will Post Earnings of -$0.96 Per Share
www.americanbankingnews.com - May 23 at 5:15 AM
Aerie Pharmaceuticals (AERI) Director Gerald D. Cagle Buys 1,000 SharesAerie Pharmaceuticals (AERI) Director Gerald D. Cagle Buys 1,000 Shares
www.americanbankingnews.com - May 22 at 8:14 PM
Aerie Pharmaceuticals (AERI) Receives Average Rating of "Buy" from AnalystsAerie Pharmaceuticals (AERI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 21 at 3:34 PM
Are Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) Interest Costs Too High?Are Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) Interest Costs Too High?
finance.yahoo.com - May 18 at 9:20 AM
BRIEF-Aerie Pharmaceuticals Submits NDA To US FDA For RoclatantmBRIEF-Aerie Pharmaceuticals Submits NDA To US FDA For Roclatantm
www.reuters.com - May 17 at 8:55 AM
Aerie Pharmaceuticals Submits New Drug Application to US Food and Drug Administration for RoclatanAerie Pharmaceuticals Submits New Drug Application to US Food and Drug Administration for Roclatan
www.businesswire.com - May 17 at 8:55 AM
Traders Buy Large Volume of Put Options on Aerie Pharmaceuticals (AERI)Traders Buy Large Volume of Put Options on Aerie Pharmaceuticals (AERI)
www.americanbankingnews.com - May 16 at 6:36 AM
Aerie Pharmaceuticals (AERI) & Windtree Therapeutics (WINT) Critical AnalysisAerie Pharmaceuticals (AERI) & Windtree Therapeutics (WINT) Critical Analysis
www.americanbankingnews.com - May 16 at 3:16 AM
Aerie submits second drug for FDA approvalAerie submits second drug for FDA approval
finance.yahoo.com - May 15 at 5:27 PM
Aerie Pharmaceuticals (AERI) Stock Rating Reaffirmed by Canaccord GenuityAerie Pharmaceuticals (AERI) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - May 15 at 5:23 PM
Aerie Pharma (AERI) Submits NDA to FDA for Roclatan 0.02%/0.005%Aerie Pharma (AERI) Submits NDA to FDA for Roclatan 0.02%/0.005%
www.streetinsider.com - May 15 at 9:02 AM
Aerie Pharma submits U.S. application for eye drop RoclatanAerie Pharma submits U.S. application for eye drop Roclatan
seekingalpha.com - May 15 at 9:02 AM
Aerie Pharmaceuticals (AERI) Lowered to "Sell" at BidaskClubAerie Pharmaceuticals (AERI) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - May 11 at 9:16 PM
Aerie Pharmaceuticals (AERI) PT Set at $78.00 by HC WainwrightAerie Pharmaceuticals (AERI) PT Set at $78.00 by HC Wainwright
www.americanbankingnews.com - May 9 at 5:12 PM
Aerie Pharmaceuticals (AERI) Releases  Earnings Results, Beats Expectations By $0.04 EPSAerie Pharmaceuticals (AERI) Releases Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - May 9 at 1:43 PM
Aerie Pharmaceuticals (AERI) Given a $86.00 Price Target at Cantor FitzgeraldAerie Pharmaceuticals (AERI) Given a $86.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 12:08 PM
Aerie Pharmaceuticals (AERI) PT Set at $86.00 by Canaccord GenuityAerie Pharmaceuticals (AERI) PT Set at $86.00 by Canaccord Genuity
www.americanbankingnews.com - May 9 at 12:08 PM
Aerie Pharmaceuticals (AERI) Buy Rating Reiterated at MizuhoAerie Pharmaceuticals' (AERI) Buy Rating Reiterated at Mizuho
www.americanbankingnews.com - May 9 at 8:52 AM
Aerie (AERI) Incurs Lower Loss in Q1, Launches RhopressaAerie (AERI) Incurs Lower Loss in Q1, Launches Rhopressa
www.zacks.com - May 9 at 8:49 AM
Aerie Pharmaceuticals (AERI) CEO Vincente Anido on Q1 2018 Results - Earnings Call TranscriptAerie Pharmaceuticals' (AERI) CEO Vincente Anido on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:49 AM
With $334M in cash, Aerie preps to break evenWith $334M in cash, Aerie preps to break even
finance.yahoo.com - May 9 at 8:49 AM
BRIEF-Aerie Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.83BRIEF-Aerie Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.83
www.reuters.com - May 8 at 5:10 PM
Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business UpdateAerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - May 8 at 5:10 PM
Aerie: 1Q Earnings SnapshotAerie: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:10 PM
Zacks: Brokerages Expect Aerie Pharmaceuticals (AERI) to Announce -$0.89 Earnings Per ShareZacks: Brokerages Expect Aerie Pharmaceuticals (AERI) to Announce -$0.89 Earnings Per Share
www.americanbankingnews.com - May 5 at 7:15 PM
Investor Expectations to Drive Momentum within Roper Technologies, Inter ...Investor Expectations to Drive Momentum within Roper Technologies, Inter ...
globenewswire.com - May 3 at 5:01 PM
Aerie Pharmaceuticals (AERI) Scheduled to Post Earnings on TuesdayAerie Pharmaceuticals (AERI) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 2 at 8:32 PM
Aerie Pharma (AERI) Announces U.S. Launch of Rhopressa 0.02%Aerie Pharma (AERI) Announces U.S. Launch of Rhopressa 0.02%
www.streetinsider.com - May 2 at 5:11 PM
Durham pharma launches first drug with another on horizonDurham pharma launches first drug with another on horizon
finance.yahoo.com - May 1 at 4:57 PM
Mizuho Trims Aerie Pharmaceuticals (AERI) Target Price to $77.00Mizuho Trims Aerie Pharmaceuticals (AERI) Target Price to $77.00
www.americanbankingnews.com - May 1 at 10:02 AM
Aerie Pharmaceuticals Announces Appointment of Concetta Perro as Commercial CounselAerie Pharmaceuticals Announces Appointment of Concetta Perro as Commercial Counsel
finance.yahoo.com - May 1 at 8:51 AM
Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa ® (netarsudil ophthalmic solution) 0.02%Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa ® (netarsudil ophthalmic solution) 0.02%
www.businesswire.com - April 30 at 4:56 PM
BRIEF-Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02%BRIEF-Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02%
www.reuters.com - April 30 at 4:56 PM
Aerie Pharma launches Rhopressa in U.S.Aerie Pharma launches Rhopressa in U.S.
seekingalpha.com - April 30 at 4:56 PM
Aerie Pharmaceuticals Announces US Launch of RhopressaAerie Pharmaceuticals Announces US Launch of Rhopressa
www.businesswire.com - April 30 at 8:50 AM
Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution) 0.02%Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution) 0.02%
finance.yahoo.com - April 30 at 8:50 AM
BRIEF-Aerie Pharmaceuticals CEO Vicente Anidos 2017 Total Compensation Was $10.06 MillionBRIEF-Aerie Pharmaceuticals CEO Vicente Anido's 2017 Total Compensation Was $10.06 Million
www.reuters.com - April 27 at 4:58 PM
Aerie Pharmaceuticals (AERI) Receives Consensus Recommendation of "Buy" from AnalystsAerie Pharmaceuticals (AERI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 26 at 3:30 PM
Stifel Nicolaus Raises Aerie Pharmaceuticals (AERI) Price Target to $65.00Stifel Nicolaus Raises Aerie Pharmaceuticals (AERI) Price Target to $65.00
www.americanbankingnews.com - April 19 at 11:52 PM
Critical Survey: Cellectis (CLLS) & Aerie Pharmaceuticals (AERI)Critical Survey: Cellectis (CLLS) & Aerie Pharmaceuticals (AERI)
www.americanbankingnews.com - April 18 at 11:10 PM
-$0.89 EPS Expected for Aerie Pharmaceuticals (AERI) This Quarter-$0.89 EPS Expected for Aerie Pharmaceuticals (AERI) This Quarter
www.americanbankingnews.com - April 18 at 7:08 PM
Aerie Pharmaceuticals (AERI) Upgraded to "Hold" by Zacks Investment ResearchAerie Pharmaceuticals (AERI) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 17 at 1:54 PM
Aerie Pharmaceuticals Target of Unusually High Options Trading (AERI)Aerie Pharmaceuticals Target of Unusually High Options Trading (AERI)
www.americanbankingnews.com - April 17 at 7:33 AM
Aerie Pharmaceuticals (AERI) Upgraded at Zacks Investment ResearchAerie Pharmaceuticals (AERI) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 16 at 9:17 PM
Aerie Pharmaceuticals (AERI) Raised to "Sell" at BidaskClubAerie Pharmaceuticals (AERI) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - April 16 at 7:35 PM
Aerie Pharmaceuticals (AERI) "Buy" Rating Reiterated at Stifel NicolausAerie Pharmaceuticals' (AERI) "Buy" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - April 15 at 11:35 AM
Aerie Pharmaceuticals (AERI) Given a $65.00 Price Target by Canaccord Genuity AnalystsAerie Pharmaceuticals (AERI) Given a $65.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 14 at 11:49 AM
Canaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $65.00 Price TargetCanaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $65.00 Price Target
www.americanbankingnews.com - April 12 at 11:27 AM

SEC Filings

Aerie Pharmaceuticals (NASDAQ:AERI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aerie Pharmaceuticals (NASDAQ:AERI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aerie Pharmaceuticals (NASDAQ AERI) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.